Oncology Institute (NASDAQ:STLN) Major Shareholder Jorey Chernett Purchases 12,000 Shares of Stock

Oncology Institute, Inc. (NASDAQ:STLN) major shareholder Jorey Chernett bought 12,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $6.54 per share, for a total transaction of $78,480.00. Following the completion of the acquisition, the insider owned 10,660,858 shares in the company, valued at approximately $69,722,011.32. This trade represents a 0.11% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Oncology Institute Stock Down 1.0%

NASDAQ:STLN traded down $0.07 during trading hours on Monday, hitting $6.38. The company’s stock had a trading volume of 310,018 shares, compared to its average volume of 1,903,016. The firm has a market capitalization of $631.09 million, a PE ratio of -21.30 and a beta of 0.39. Oncology Institute, Inc. has a twelve month low of $2.32 and a twelve month high of $7.05.

Analysts Set New Price Targets

Separately, Weiss Ratings initiated coverage on shares of Oncology Institute in a research note on Thursday, August 6th. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Oncology Institute Company Profile

Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.

The company’s business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.